Guggenheim Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $40.00

Unicycive Therapeutics (NASDAQ:UNCY) had its price objective lowered by Guggenheim from $46.00 to $40.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. Westpark Capital started coverage on shares of Unicycive Therapeutics in a report on Thursday, February 19th. They set a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Unicycive Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $27.67.

Unicycive Therapeutics Price Performance

Shares of NASDAQ:UNCY opened at $6.93 on Thursday. The business’s 50 day moving average price is $6.67 and its 200-day moving average price is $5.82. The firm has a market capitalization of $174.91 million, a PE ratio of -3.19 and a beta of 1.81. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.36). As a group, analysts expect that Unicycive Therapeutics will post -0.23 earnings per share for the current year.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UNCY. Quadrature Capital Ltd acquired a new position in Unicycive Therapeutics during the fourth quarter worth $226,000. Millennium Management LLC acquired a new stake in shares of Unicycive Therapeutics in the 4th quarter worth $5,856,000. Cantor Fitzgerald L. P. acquired a new stake in shares of Unicycive Therapeutics in the 4th quarter worth $1,154,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Unicycive Therapeutics during the 4th quarter worth $451,000. Finally, State Street Corp raised its holdings in shares of Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after acquiring an additional 10,400 shares during the period. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed a Buy on Unicycive, maintaining analyst support that can sustain demand among growth/biotech investors. Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)
• Positive Sentiment: Guggenheim kept a Buy rating and a high $40 price target (down from $46), signaling continued bullish conviction and large upside vs. the current share price — a support for longer‑term investors. Benzinga
• Positive Sentiment: Coverage from Noble Financial includes a reportedly positive Q3 outlook and modest intraquarter upward tweaks, which may limit downside for near‑term earnings expectations. Noble Financial Has Positive Forecast for UNCY Q3 Earnings
• Neutral Sentiment: Noble Financial made small upward revisions to certain near‑term quarters (Q1 and a slight Q2 tweak), but also trimmed its FY2026 outlook — a mixed signal that tempers how much the stock should move on those changes alone.
• Negative Sentiment: HC Wainwright issued broad downgrades across Q2–Q4 2026 and materially cut FY2026–FY2030 EPS forecasts (FY2026 from ~($0.94) to ($1.67); FY2028–FY2030 reductions are especially large). Those cuts imply slower near‑term profitability and push out the path to the previously modeled upside, which is likely the main driver of downward pressure on the share price.
• Negative Sentiment: Noble also lowered its Q4 2026 and FY2026 numbers in the same reporting window, which adds further downward bias to consensus near‑term earnings expectations.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.